TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES

1 . A random copolymer of Formula I:

I.

wherein

each M 1 and M 2 are independently selected from the group consisting of acrylate, methacrylate, acrylamide, methacrylamide, styrene, vinyl-pyridine and vinyl-pyrrolidone;

R 1 is selected from the group consisting of H, L 1 -A 1 , LG 1 and L 1 -LG 1 ;

each R 2 is independently selected from the group consisting of H, C 1-20 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 heteroalkyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, aryl, heteroaryl, A 2 , L 2 -A 2 , LG 2 , L 2 -LG 2 , I 2 and L 2 -I 2 ;

ZW is a zwitterionic moiety;

I and I′ are each independently an initiator fragment, such that the combination of I—I′ is an initiator, I 1 , for the polymerization of the random copolymer of Formula I;

alternatively, I′ is selected from the group consisting of H and C 1-6 alkyl;

I 2 is an initiator;

each of L 1 and L 2 is a linker;

each of A 1 and A 2 is a functional agent;

each of LG 1 and LG 2 is a linking group;

subscripts x and y 1 are each independently an integer of from 1 to 1000;

subscript z is an integer of from 1 to 10;

subscript s is an integer of from 1 to 100; and

subscript n is an integer of from 1 to 20,

wherein either R 1 is L 1 -A 1 or one of R 2 is L 2 -A 2 .

2 . The random copolymer of claim 1 , wherein the random copolymer has the formula:

3 . The random copolymer of claim 1 , having the formula:

4 . The random copolymer of claim 1 , wherein at least one R 2 is selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 heteroalkyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, aryl, and heteroaryl.

5 . The random copolymer of claim 1 , wherein the random copolymer has the formula:

each of R 3 and R 4 are independently selected from the group consisting of H and C 1-6 alkyl; and

PC is phosphatidylcholine.

6 . The random copolymer of claim 5 , wherein the random copolymer has the formula:

7 . The random copolymer of claim 6 , wherein the random copolymer has the formula:

wherein A 2 is camptothecin.

8 . The random copolymer of claim 1 , wherein each of L 1 and L 2 is a cleavable linker independently selected from the group consisting of hydrolyzable linkers, enzymatically cleavable linkers, pH sensitive linkers, disulfide linkers and photolabile linkers.

9 . The random copolymer of claim 1 , wherein the functional agent is a bioactive agent selected from the group consisting of a drug, a therapeutic protein and a targeting agent.

10 . The random copolymer of claim 1 , wherein the initiator fragment I′ is a halogen.

11 . The random copolymer of claim 1 , wherein the initiator I 1 is selected from the group consisting of:

12 . A process for preparing a random copolymer, the process comprising:

contacting a mixture of a first monomer and a second monomer with an initiator, I 1 , under conditions sufficient to prepare a random copolymer via free radical polymerization, wherein the first monomer comprises a phosphorylcholine, and each of the second monomer and initiator independently comprise at least one of a functional agent or a linking group for linking to the functional agent.

13 . The process of claim 12 , wherein the mixture further comprises a catalyst and a ligand.

14 . A method of treating cancer, comprising administering a therapeutically effective amount of the random copolymer of claim 1 to a subject in need thereof, thereby treating cancer.

15 . The method of claim 14 , wherein the random copolymer has the formula of

wherein A 2 is camptothecin.